Frontiers in Clinical Drug Research-Diabetes and Obesity

Volume: 2

Antidiabetic Drugs of Type 2 Diabetes and Obesity

Author(s): Tatjana Ábel and Gabriella Lengyel

Pp: 50-59 (10)

Doi: 10.2174/9781681081854116020004

* (Excluding Mailing and Handling)

Abstract

Overweight and obesity are risk factors for type 2 diabetes, and they also influence the overall prognosis. Almost 90 % of type 2 diabetic subjects are overweight and more than half are obese. Type 2 diabetes is a progressive metabolic disorder conferring an increased risk of cardiovascular comorbidities, including hypertension, coronary artery disease and stroke. The availability of several different classes of antidiabetic drugs in the last few years has increased the number of choices for physicians. The aim of these therapies is to reduce and maintain glucose concentrations and thereby prevent development of complications. When choosing between different antidiabetic drugs attention should be paid to their effect on body weight too.


Keywords: Adipose tissue, antidiabetic, BMI, bromocriptine, carbohydrate, colesevelam, complication, diabetes, DPP4 inhibitors; gastrointestinal, glinides, GLP-1 receptor agonists, HbA1c, hypoglycemia, hypothalamus, insulin, kidney, metabolism, metformin, obesity, pramlintide, SGLT2 inhibitors, sulfonylurea, thiazolidinedione.

Related Journals
Related Books
© 2022 Bentham Science Publishers | Privacy Policy